Artículos por temáticas

Impact of AP@LZ in the daily life of three persons with Alzheimer's disease: long-term use and further exploration of its effectiveness

Imbeault H, Gagnon L, Pigot H, Giroux S, Marcotte N, Cribier-Delande P, Duval J, Bocti C, Lacombe G, Fülöp T, Bier N.

Neuropsychol Rehabil. 2018 Jul;28(5):755-778. doi: 10.1080/09602011.2016.1172491. Epub 2016 Apr 28.

Gender Differences in Neuropsychiatric Symptoms in Mild to Moderate Alzheimer's Disease Patients Undergoing Switch of Cholinesterase Inhibitors: A Post Hoc Analysis of the EVOLUTION Study

Colombo D, Caltagirone C, Padovani A, Sorbi S, Spalletta G, Simoni L, Ori A, Zagni E.

J Womens Health (Larchmt). 2018 Nov;27(11):1368-1377. doi: 10.1089/jwh.2017.6420. Epub 2018 Sep 8.

Association of Concomitant Use of Cholinesterase Inhibitors or Memantine With Cognitive Decline in Alzheimer Clinical Trials: A Meta-analysis

Kennedy RE, Cutter GR, Fowler ME, Schneider LS.

JAMA Netw Open. 2018 Nov 2;1(7):e184080. doi: 10.1001/jamanetworkopen.2018.4080.

The Value of Pre-Screening in the Alzheimer's Prevention Initiative (API) Autosomal Dominant Alzheimer's Disease Trial

Rios-Romenets S, Giraldo-Chica M, López H, Piedrahita F, Ramos C, Acosta-Baena N, Muñoz C, Ospina P, Tobón C, Cho W, Ward M, Langbaum JB, Tariot PN, Reiman EM, Lopera F.

J Prev Alzheimers Dis. 2018;5(1):49-54. doi: 10.14283/jpad.2017.44.

Longitudinal Neuroimaging Analysis in Mild-Moderate Alzheimer's Disease Patients Treated with Plasma Exchange with 5% Human Albumin

Cuberas-Borrós G, Roca I, Boada M, Tárraga L, Hernández I, Buendia M, Rubio L, Torres G, Bittini Á, Guzmán-de-Villoria JA, Pujadas F, Torres M, Núñez L, Castell J, Páez A.

J Alzheimers Dis. 2018;61(1):321-332. doi: 10.3233/JAD-170693.

Effect of Physical Activity on the Progression of Alzheimer's Disease: The Clinical Research Center for Dementia of South Korea Study

Minn YK, Choi SH, Suh YJ, Jeong JH, Kim EJ, Kim JH, Park KW, Park MH, Youn YC, Yoon B, Choi SJ, Oh YK, Yoon SJ.

J Alzheimers Dis. 2018;66(1):249-261. doi: 10.3233/JAD-180333.

Safety, tolerability and immunogenicity of an active anti-Aβ(40) vaccine (ABvac40) in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase I trial

Lacosta AM, Pascual-Lucas M, Pesini P, Casabona D, Pérez-Grijalba V, Marcos-Campos I, Sarasa L, Canudas J, Badi H, Monleón I, San-José I, Munuera J, Rodríguez-Gómez O, Abdelnour C, Lafuente A, Buendía

Alzheimers Res Ther. 2018 Jan 29;10(1):12. doi: 10.1186/s13195-018-0340-8.

Neuroprotective Activity of Sitagliptin via Reduction of Neuroinflammation beyond the Incretin Effect: Focus on Alzheimer's Disease

Wiciński M, Wódkiewicz E, Słupski M, Walczak M, Socha M, Malinowski B, Pawlak-Osińska K.

Biomed Res Int. 2018 Aug 16;2018:6091014. doi: 10.1155/2018/6091014. eCollection 2018.

Memantine in Japanese patients with moderate to severe Alzheimer's disease: meta-analysis of multiple-index responder analyses

Okuizumi K, Kamata T, Matsui D, Saito K, Matsumoto T, Fukuchi Y.

Expert Opin Pharmacother. 2018 Apr;19(5):425-430. doi: 10.1080/14656566.2018.1442440. Epub 2018 Mar 6.

[Nursing home placement of people with dementia: a secondary analysis of qualitative data and literature review on perspectives of informal caregivers and healthcare professionals]

Nguyen N, Renom-Guiteras A, Meyer G, Stephan A.

Pflege. 2018 Jun;31(3):155-166. doi: 10.1024/1012-5302/a000611. Epub 2018 Mar 8.

Helping Hispanic Dementia Caregivers Cope with Stress Using Technology-based Resources

Kajiyama B, Fernandez G, Carter EA, Humber MB, Thompson LW.

Clin Gerontol. 2018 May-Jun;41(3):209-216. doi: 10.1080/07317115.2017.1377797. Epub 2017 Dec 13.

Short-Term Response to Cholinesterase Inhibitors in Alzheimer's Disease Delays Time to Nursing Home Placement

Wattmo C, Londos E, Minthon L.

Curr Alzheimer Res. 2018;15(10):905-916. doi: 10.2174/1567205015666180507105326.

Beneficial Effect of Multidomain Cognitive Training on the Neuropsychological Performance of Patients with Early-Stage Alzheimer's Disease

Nousia A, Siokas V, Aretouli E, Messinis L, Aloizou AM, Martzoukou M, Karala M, Koumpoulis C, Nasios G, Dardiotis E.

Neural Plast. 2018 Jul 11;2018:2845176. doi: 10.1155/2018/2845176. eCollection 2018.

Long-Term Follow Up of Patients with Mild-to-Moderate Alzheimer's Disease Treated with Bapineuzumab in a Phase III, Open-Label, Extension Study

Salloway SP, Sperling R, Fox NC, Sabbagh MN, Honig LS, Porsteinsson AP, Rofael H, Ketter N, Wang D, Liu E, Carr S, Black RS, Brashear HR.

J Alzheimers Dis. 2018;64(3):689-707. doi: 10.3233/JAD-171157.

A Phase 2 clinical trial of PF-05212377 (SAM-760) in subjects with mild to moderate Alzheimer's disease with existing neuropsychiatric symptoms on a stable daily dose of donepezil

Fullerton T, Binneman B, David W, Delnomdedieu M, Kupiec J, Lockwood P, Mancuso J, Miceli J, Bell J.

Alzheimers Res Ther. 2018 Apr 5;10(1):38. doi: 10.1186/s13195-018-0368-9.